ArticleScientific reports2024
Technical development and application of supercritical CO
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 23 citations in OpenAlex.
- Green and Scalable Manufacturing of Biodegradable Polymer Scaffolds: Solvent-Free Processing, Supercritical COPolymers · 2026Review
- Application of PLCL as a biodegradable polymer in biomedical engineering.Journal of materials science. Materials in medicine · 2026Review
- COGels (Basel, Switzerland) · 2025Article
- The Future of Sustainable Packaging: Exploring Biodegradable Solutions Through Extrusion, Thermo-Expansion, 3D Printing and Supercritical Fluid from Agro-Industry Waste.Foods (Basel, Switzerland) · 2025Review
- Biocompatible Thermoplastics in Additive Manufacturing of Bone Defect Fillers: State-of-the-Art and Future Prospects.Materials (Basel, Switzerland) · 2025Review
- Preclinical Evidence That Mesoglycan Unfolds Complex Anti-Aging Effects in Photoaged Female Facial Skin.International journal of molecular sciences · 2025Article
- Emerging biomimetic biopolymer-based composites: advancing accessible and sustainable neural disease models and therapeutics.Frontiers in bioengineering and biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Polycaprolactone (PCL) has the advantages of good biocompatibility, appropriate biodegradability, non-toxicity, flexibility, and processability. As a result, PCL-based foams can successfully work in bone tissue engineering, medical patches, drug delivery, reinforcing materials, and other applications. A promising technology for producing PCL foam products is supercritical CO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.